What does AIM ImmunoTech Inc. (AIM) do?

AIM ImmunoTech Inc. (AIM) is a publicly traded company in the Healthcare sector.

What sector does AIM operate in?

AIM ImmunoTech Inc. operates in the Healthcare, specifically within the Biotechnology industry. AlphaOS tracks cycle stage, supply-chain relationships, and investment intelligence for companies across all sectors.

Where can I find AIM earnings analysis?

AlphaOS publishes an earnings intelligence page for AIM ImmunoTech Inc. (AIM) covering results, guidance context, and AI-assisted analysis. See /stocks/AIM/earnings. Content is for research and education — not investment advice.

Intelligence coverage: 60%

Basic profile, financials, and market data are shown below. Deep research is building in the background.

AIM

AIM ImmunoTech Inc.

Healthcare · Biotechnology

$0.19Sep 25, 2026

AI confidence 59% · refreshes every 15s during session

Investment Snapshot

Weak evidence · 1 source

Why it matters

AIM ImmunoTech Inc. shows decelerating business momentum based on AlphaOS pipeline evidence.

Why it matters: Revenue +4% YoY in Q2 FY2026.

TrajectoryDecelerating

3 signals not yet derived from pipeline evidence

Key signals

What it means for the thesis — synthesis, not a raw event feed.

Revenue +4% YoY in Q2 FY2026

Pipeline evidence · 1d ago

AIM's AlphaOS Signals

Upgrade to Pro for validated historical pattern analysis on AIM.

Create free account

Free accounts see more of this; Premium sees all of it.

Latest earnings · Q2 2026

Full AIM earnings analysis

Reported figures for AIM ImmunoTech Inc. — research only, not investment advice.

Revenue YoY: +4.0%

Latest Intelligence

Updated September 27, 2026

What happened recently for AIM ImmunoTech Inc. (AIM) — events, not interpretation.

Event: Reported Q2 2026 revenue +4% YoY.
Also: Last session September 25, 2026 at $0.19.
Source: Q2 2026 earnings

Research & analysis only — not investment advice.

Industry & ETF context

Industry blend 59

Primary industry Biotechnology scores 59/100 (Early Recovery cycle, Strong momentum).

AlphaOS industries

Biotechnology

Primary

Score 59Early RecoveryStrong momentum

Investment snapshot

AIM ImmunoTech Inc.

AIM's opportunity score

Upgrade to Premium

Analysis confidence: 59%

AIM's AI investment thesis

Upgrade to Premium for AIM's full multi-agent investment thesis.

Create free account

Free accounts see more of this; Premium sees all of it.

59% confidence

Intelligence layer

Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity

PricesFinancialsFilingsFiling insightsEarningsEarnings AITranscriptsTechnicalOpportunityResearch

→Filing signal: Potential insider selling

Strengthen intelligence

· Run earnings AI analysis on latest quarter
· Fetch earnings call transcript for CEO commentary

Latest price

$0.19

Market cap

$5.79M

Profitable

Revenue $88,000.00

Net income

$-13.96M

FY Dec 31, 2025

Analyst ratings

Loading Wall Street consensus…

Earnings intelligence

Full earnings center

Loading earnings intelligence…

Technical intelligence

Building technical intelligence snapshot — check back shortly.

Loading market context…

Price & volume

0 trading days

No price history. Sync market data to load charts.

Filing insights

Loading SEC filing intelligence…

Competitive landscape

Recent SEC filings

Filings tab

No filings ingested yet.

AIM ImmunoTech Inc. (AIM)

Healthcare · Biotechnology

Investment Snapshot above is the primary AlphaOS analysis for AIM ImmunoTech Inc. — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.